Modified fatty acids and their possible therapeutic targets in malignant diseases

Bibliography

• JOSEFSON D: Obesity and inactivity fuel global cancer epidemic. BMJ(2001) 322(7292):945.
   PubMedGoogle Scholar
• PETO J: Cancer epidemiology in the last century and the next decade. Nature (2001) 411(6835):390–395.
   PubMed Web of Science ®Google Scholar
• PAUMEN MB, ISHIDA Y, MURAMATSU M, YAMAMOTO M, HONJO T: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. Biol. Chem. (1997) 272(6):3324–3329.
   Web of Science ®Google Scholar
• DE PABLO MA, SUSIN SA, JACOCOT E et al.: Palmitate induces apoptosis via a direct effect on mitochondria. Apoptosis (1999) 4:81–97.
   PubMed Web of Science ®Google Scholar
• SANTINI V, GOZZINI A, SCAPPINI B,GROSSI A, ROSSI FERRINI P: Searching for the magic bullet against cancer: the butyrate saga. Leak. Lymphoma (2001) 42(3):275–289.
   PubMed Web of Science ®Google Scholar
• PARIZA MW, PARK Y, COOK ME: Conjugated linoleic acid and the control of cancer and obesity. Toxica Sci. (1999) 52(2 Suppl.):107–110.
   Google Scholar
• PINEAU T, HUD GINS WR, LIU L et al.: Activation of a human perwdsome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol. (1996) 52(4):659–667.
   PubMed Web of Science ®Google Scholar
• SAMID D, RAM Z, HUDGINS WR et aL: Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. (1994) 54(4):891–895.
   PubMed Web of Science ®Google Scholar
• HONG WK, LIPPMAN SM, ITRI LM et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl.' Med. (1990) 323(12):795–801.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, KAVANAGH JJ, PAREDES-ESPINOZA M et al.: 13-cis-retinoic acid plus interferon a-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. Nati Cancer Inst. (1992) 84(4):241–245.
   PubMedGoogle Scholar
• BRUSERUD O, GJERTSEN BT: New strategies for the treatment of acute myelogenous leukemia: differentiation induction — present use and future possibilities. Stem Cells (2000) 18(3):157–165.
   PubMed Web of Science ®Google Scholar
• JIANG WG, BRYCE RP, HORROBIN DF: Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit. Rev Oncol. Hematol. (1998) 27(3):179–209.
   PubMed Web of Science ®Google Scholar
• KUMAR GS, DAS UN: Free radical-dependent suppression of growth of mouse myeloma cells by a-linolenic and eicosapentaenoic acids M vitro. Cancer Lett. (1995) 92(1):27–38.
   PubMed Web of Science ®Google Scholar
• SEBTI SM, TKALCEVIC GT, JANI JP: Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun. (1991) 3(5):141–147. 39.
   Google Scholar
• LENZ M, MIEHE WP, VAHRENWALD F, BRUCHELT G, SCHWEIZER P, GIRGERT R: Cholesterol based antineoplastic strategies. Anticancer Res. (1997) 17(2A):1143–1146.
   Google Scholar
• OSTRANDER DB, SPARAGNA GC, AMOSCATO AA, MCMILLIN JB, DOWHAN W: Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J. Biol. Chem. (2001) 276(41):38061–38067.
   PubMed Web of Science ®Google Scholar
• ESPOSTI MD: Lipids, cardiolipin and apoptosis: a greasy licence to kill. Cell Death Differ. (2002) 9(3):234–236.
   PubMed Web of Science ®Google Scholar
• PALAKURTHI SS, FLUCKIGER R, AKTAS H et al.: Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. (2000) 60(11):2919–2925.
   PubMed Web of Science ®Google Scholar
• DAS UN: Essential fatty acids, lipid perwddation and apoptosis. Prostaglandins Leukot. Essent. Fatty Acids (1999) 61(3):157–163.
   PubMed Web of Science ®Google Scholar
• JENUWEIN T, ALLIS CD: Translating the histone code. Science (2001) 293(5532):1074–1080.
   PubMed Web of Science ®Google Scholar
• GRUNSTEIN M: Histone acetylation in chromatin structure and transcription. Nature (1997) 389(6649):349–352.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, RIFKIND RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Nail Cancer Inst. (2000) 92(15):1210–1216.
   PubMed Web of Science ®Google Scholar
• •Excellent review of HDAC inhibitors as new cancer drugs, and their mechanism of action.
   Google Scholar
• MARKS P, RIFKIND RA, RICHON VM, BRESLOW R, MILLER T, KELLY WK: Histone deacetylases and cancer: causes and therapies. Nat. Rev Cancer (2001) 1(3):194–202.
   PubMed Web of Science ®Google Scholar
• RICHON VM, O'BRIEN JP: Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Gin. Cancer Res. (2002) 8(3):662–664.
   Web of Science ®Google Scholar
• KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs (2002) 11(12):1695–1713.
   PubMed Web of Science ®Google Scholar
• VAN LINT C, EMILIANI S, VERDIN E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expc (1996) 5(4-5):245–253.
   PubMed Web of Science ®Google Scholar
• KIM YB, LEE KH, SUGITA K, YOSHIDA M, HORINOUCHI S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18(15):2461–2470.
   PubMed Web of Science ®Google Scholar
• MATSUYAMA A, SHIMAZU T, SUMIDA Y et al.: In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. (2002) 21(24):6820–6831.
   PubMed Web of Science ®Google Scholar
• LIN RJ, NAGY L, INOUE S, SHAO W, MILLER WH Jr, EVANS RIVI: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 391(6669):811–814.
   PubMed Web of Science ®Google Scholar
• GRIGNANI F, DE MATTEIS S, NERVI C et al.: Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391(6669):815–818.
   PubMed Web of Science ®Google Scholar
• GORE SD, CARDUCCI MA: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs (2000) 9(12):2923–2934.
   PubMed Web of Science ®Google Scholar
• BLAHETA RA, CINATL J Jr: Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev (2002) 22(5):492–511.
   PubMed Web of Science ®Google Scholar
• GILLET R, JEANNESSON P, SEFRAOUI H et al.: Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells. Cancer Chemothec Pharmacol (1998) 41(3):252–255.
   PubMed Web of Science ®Google Scholar
• NUDELMAN A, GNIZI E, KATZ Y et al: pro-drugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur. J. Med. Chem. (2001) 36(1):63–74.
   Google Scholar
• GORE SD, SAMID D, WENG LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. (1997) 3(10):1755–1762.
   PubMed Web of Science ®Google Scholar
• SAMID D, HUD GINS WR, SHACK S, LIU L, PRASANNA P, MYERS CE: Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol. (1997) 400A:501–505.
   PubMedGoogle Scholar
• JUNG M: Inhibitors of histone deacetylase as new anticancer agents. Carr: Med. Chem. (2001) 8(12):1505–1511.
   PubMed Web of Science ®Google Scholar
• HARRISON LE, WOJCIECHOWICZ DC, BRENNAN ME PATY PB: Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery (1998) 124(3):541–550.
   PubMed Web of Science ®Google Scholar
• SAMID D, WELLS M, GREENE ME, SHEN W, PALMER CN, THIBAULT A: Peroxisome proliferator-activated receptor y as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin. Cancer Res. (2000) 6(3):933–941.
   PubMed Web of Science ®Google Scholar
• •Interesting report pointing out PPARy as a novel target in cancer therapy by showing a correlation between the expression status and activation of the receptor, and the cytostatic effect of phenylacetate and derivatives in various cell lines.
   Google Scholar
• SANTINI V, GOZZINI A, SCAPPINI B et al.: Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells. Haematologica (1999) 84(10):897–904.
   PubMed Web of Science ®Google Scholar
• SANTINI V, SCAPPINI B, GOZZINI A et al.: Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. Br. J. Haematol (1998) 101(3):529–538.
   PubMed Web of Science ®Google Scholar
• HEERDT BG, HOUSTON MA, AUGENLICHT LH: Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res. (1994) 54(12):3288–3293.
   PubMed Web of Science ®Google Scholar
• MILOVIC V, TELLER IC, TURCHANOWA L, CASPARY WE STEIN J: Effect of structural analogues of propionate and butyrate on colon cancer cell growth. Int. J. Colorectal. Dis. (2000) 15(5-6):264–270.
   PubMed Web of Science ®Google Scholar
• GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. (2001) 20(24):6969–6978.
   PubMed Web of Science ®Google Scholar
• ••Important study demonstrating thatvalproic acid inhibits co-repressor-associated HDACs and acts as an inducer of differentiation in several cell lines and in primary leukaemia blasts.
   Google Scholar
• FONTANA JA, RISHI AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia (2002) 16(4):463–472.
   PubMed Web of Science ®Google Scholar
• •An up-to-date review on novel retinoids, their mechanism of action and their potential as therapeutic agents in the treatment of malignant disorders.
   Google Scholar
• BRUSERUD O, GJERTSEN BT, HUANG T: Induction of differentiation and apoptosis - a possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist (2000) 5 (6) : 454–462.
   PubMedGoogle Scholar
• TALLMAN MS, NABHAN C, FEUSNERJH, ROWE JM: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood (2002) 99(3):759–767.
   PubMed Web of Science ®Google Scholar
• KAKIZUKA A, MILLER WH Jr, UMESONO K et al: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses PAR a with a novel putative transcription factor, PML. Cell (1991) 66(4):663–674.
   PubMed Web of Science ®Google Scholar
• ZHANG C, HAZARIKA P, NI X, WEIDNER DA, DUVIC M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin. Cancer Res. (2002) 8(5):1234–1240.
   PubMed Web of Science ®Google Scholar
• WU K, ZHANG Y, XU XC et al: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. (2002) 62(22):6376–6380.
   PubMed Web of Science ®Google Scholar
• KHURI FR, RIGAS JR, FIGLIN RA et al.: Multi-institutional Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.j Clin. Oncol (2001) 19(10):2626–2637.
   Google Scholar
• WU JM, DIPIETRANTONIO AM, HSIEH TC: Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis (2001) 6(5):377–388.
   PubMed Web of Science ®Google Scholar
• COSTANTINI P, JACOTOT E, DECAUDIN D, KROEMER G: Mitochondrion as a novel target of anticancer chemotherapy. J. Nati Cancer Inst. (2000) 92(13):1042–1053.
   PubMed Web of Science ®Google Scholar
• ••Excellent review summarising theinvolvement of mitochondria in the action of anticancer drugs. The authors suggest that the design of mitochondrion-targeted cytotoxic drugs may constitute a novel strategy for overcoming apoptosis resistance in cancer cells.
   Google Scholar
• DEMETRI GD, FLETCHER CD, MUELLER E et al: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-y ligand troglitazone in patients with liposarcoma. Proc. Nati Acad. Sci. USA (1999) 96(7):3951–3956.
   PubMed Web of Science ®Google Scholar
• MUELLER E, SMITH M, SARRAF P et al.: Effects of ligand activation of peroxisome proliferator-activated receptor y in human prostate cancer. Proc. Natl. Acad. Sci. USA (2000) 97(20):10990–10995.
   PubMed Web of Science ®Google Scholar
• SARRAF P, MUELLER E, JONES D et al:Differentiation and reversal of malignant changes in colon cancer through PPARy. Nat. Med. (1998) 4(9):1046–1052.
   PubMed Web of Science ®Google Scholar
• MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal differentiation of human breast cancer through PPARy. MM. Cell (1998) 1(3):465–470.
   PubMed Web of Science ®Google Scholar
• ELSTNER E, MULLER C, KOSHIZUKA K et al: Ligands for peroxisome proliferator-activated receptor y and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA (1998) 95(15):8806–8811.
   PubMed Web of Science ®Google Scholar
• KUBOTA T, KOSHIZUKA K, WILLIAMSON EA et al.: Ligand for peroxisome proliferator-activated receptor y (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. (1998) 58(15)3344–3352.
   Google Scholar
• SAEZ E, TONTONOZ P, NELSON MC et al.: Activators of the nuclear receptor PPARy enhance colon polyp formation. Nat. Med. (1998) 4(9):1058–1061.
   PubMed Web of Science ®Google Scholar
• LEFEBVRE AM, CHEN I, DESREUMAUX P et al.: Activation of the peroxisome proliferator-activated receptor y promotes the development of colon tumors in C57BL/6J-APCMink mice. Nat. Med. (1998) 4(9):1053–1057.
   PubMed Web of Science ®Google Scholar
• HAN S, WADA RK, SIDELL N: Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor y. Cancer Res. (2001) 61(10):3998–4002.
   PubMed Web of Science ®Google Scholar
• BERGE K, TRONSTAD KJ, FLINDT EN et al.: Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis (2001) 22(11):1747–1755.
   PubMed Web of Science ®Google Scholar
• BERGE RK, SKORVE J, TRONSTAD KJ, BERGE K, GUDBRANDSEN OA, GRAV H: Metabolic effects of thia fatty acids. Carr. Opin. Lipidol (2002) 13(3):295–304.
   PubMed Web of Science ®Google Scholar
• TRONSTAD KJ, BRUSERUD O, BERGE K, BERGE RK: Antiproliferative effects of a non-3-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia (2002) 16(11):2292–2301.
   PubMed Web of Science ®Google Scholar
• TRONSTAD K, BERGE K, DYROY E, MADSEN L, BERGE R: Growth reduction in glioma cells after treatment with tetradecylthioacetic acid. Changes in fatty acid metabolism and oxidative status. Biochem. Pharmacol (2001) 61:639–649.
   Google Scholar
• GUPTA RA, DUBOIS RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer (2001) 1(1):11–21.
   PubMed Web of Science ®Google Scholar
• •Excellent review of how and why treatment with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.
   Google Scholar
• DEMPKE W, RIE C, GROTHEY A, SCHMOLL HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy?' Cancer Res. Clin. Oncol (2001) 127(7):411–417.
   Web of Science ®Google Scholar
• SHARMA RA: Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. WM (2002) 95(5):267–273.
   Google Scholar
• OTA S, BAMBA H, KATO A, KAWAMOTO C, YOSHIDA Y, FUJIWARA K: Review article: COX-2, prostanoids and colon cancer. Aliment. Pharmacol Ther. (2002) 16\(Suppl. 2):102–106.
   Google Scholar
• PRESCOTT SM, FITZPATRICK FA: Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta (2000) 1470(2):M69–M78.
   Web of Science ®Google Scholar
• RINGBOM T, HUSS U, STENHOLM A et al.: Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J. Nat. Prod. (2001) 64(6):745–749.
   PubMed Web of Science ®Google Scholar
• •Interesting report describing the activity and selectivity of naturally-occurring and modified fatty acids as inhibitors of COX-2.
   Google Scholar
• DIRSCH VM, VOLLMAR AM: Ajoene, a natural product with non-steroidal anti-inflammatory drug (NSAID)-like properties? Biochem. Pharmacol (2001) 61(5):587–593.
   Web of Science ®Google Scholar
• LEVINE L: Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB J. (2003) 17(8):800–802.
   Google Scholar
• ADJEI AA: Blocking oncogenic Ras signaling for cancer therapy. Nati Cancer Inst. (2001) 93(14):1062–1074.
   PubMed Web of Science ®Google Scholar
• BOS JL: ras oncogenes in human cancer: a review. Cancer Res. (1989) 49(17):4682–4689.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, PANE N: Farnesyltransferase inhibitors: mechanism and applications. Expert Opin. Investig. Drugs (2001) 10(12):2105–2116.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, WINDLE JJ, VON HOFF DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. Clin. Oncol (1999) 17(11):3631–3652.
   Web of Science ®Google Scholar
• HALUSKA P, DY GK, ADJEI AA: Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer (2002) 38(13):1685–1700.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review evaluating the existing knowledge about the anticancer activity of farnesyl transferase inhibitors.
   Google Scholar
• WONG WW, DIMITROULAKOS J, MINDEN MD, PENN LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 16(4):508–519.
   PubMed Web of Science ®Google Scholar
• ASIEDU DK, DEMOZ A, SKORVE J, GRAV HJ, BERGE RK: Acute modulation of rat hepatic lipid metabolism by sulphur-substituted fatty acid analogues. Biochem. Pharmacol (1995) 49(7):1013–1022.
   PubMed Web of Science ®Google Scholar
• COLLETT ED, DAVIDSON LA, FAN YY, LUPTON JR, CHAPKIN RS: n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am. Physiol Cell Physiol (2001) 280(5):C1066–C1075.
   Web of Science ®Google Scholar
• KROEMER G, REED JC: Mitochondrial control of cell death. Nat. Med. (2000) 6(5):513–519.
   PubMed Web of Science ®Google Scholar
• SKULACHEV VP: Fatty acid circuit as a physiological mechanism of uncoupling of oxidative phosphorylation. FEBS Lett. (1991) 294(3):158–162.
   PubMed Web of Science ®Google Scholar
• WALKER JE, RUNS WICK MJ: The mitochondrial transport protein superfamily. Bioenerg. Biomembr. (1993) 25(5):435–446.
   PubMed Web of Science ®Google Scholar
• MCMILLIN JB, DOWHAN W: Cardiolipin and apoptosis. Biochim. Biophys. Acta (2002) 1585(2-3):97–107.
   PubMed Web of Science ®Google Scholar
• JOSHI B, LI L, TAFFE BG et al: Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res. (1999) 59(17)4343–4355.
   Google Scholar
• PAUMEN MB, ISHIDA Y, HAN H et al.: Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bc1-2. Biochem. Biophys. Res. Commun. (1997) 231(3):523–525.
   PubMed Web of Science ®Google Scholar
• KONG JY, RABKIN SW: Palmitate-induced apoptosis in cardiomyocytes is mediated through alterations in mitochondria: prevention by cyclosporin A. Biochim. Biophys. Acta (2000) 1485(1):45–55.
   PubMed Web of Science ®Google Scholar
• KONG JY, RABKIN SW: Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am. J. PhysioL Heart Circ. Physiol (2002) 282(2):H717–H725.
   Web of Science ®Google Scholar
• FINSTAD HS, DYRENDAL H, MYHRSTAD MC, HEIMLI H, DREVON CA: Uptake and activation of eicosapentaenoic acid are related to accumulation of triacylglycerol in Ramos cells dying from apoptosis. J. Lipid Res. (2000) 41(4):554–563.
   PubMed Web of Science ®Google Scholar
• TRONSTAD KJ, GJERTSEN BT, KRAKSTAD C et al.: Mitochondrial-targeted fatty acid analogue induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chem. Biol. (2003) 10:609–618.
   PubMedGoogle Scholar
• MILLER AA, KURSCHEL E, OSIEKA R, SCHMIDT CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol (1987) 23(9):1283–1287.
   PubMedGoogle Scholar
• MITCHELL RB, WAGNER JE, KARP JE et al: Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am.! Med. (1988) 85(5):662–667.
   PubMed Web of Science ®Google Scholar
• CARDUCCI MA, GILBERT J, BOWLING MK et al.: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. (2001) 7(10):3047–3055.
   PubMed Web of Science ®Google Scholar
• GILBERT J, BAKER SD, BOWLING MK et al: A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. (2001) 7(8):2292–2300.
   PubMed Web of Science ®Google Scholar
• PATNAIK A, ROWINSKY EK, VILLALONA MA et al.: A Phase I study of pivaloyloxymethyl butyrate, a pro-drug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. (2002) 8(7):2142–2148.
   PubMed Web of Science ®Google Scholar
• CONLEY BA, EGORIN MJ, TAIT N et al.: Phase I study of the orally administered butyrate pro-drug, tributyrin, in patients with solid tumors. Clin. Cancer Res. (1998) 4(3):629–634.
   PubMed Web of Science ®Google Scholar
• EDELMAN MJ, BAUER K, KHANWANI S et al.: Clinical and pharmacologic study of tributyrin: an oral butyrate pro-drug. Cancer Chemother. Pharmacol (2003) 51(5):439–444.
   PubMed Web of Science ®Google Scholar
• WARRELL RP Jr, HE LZ, RICHON V, CALLEJA E, PANDOLFI PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Camrr Inst. (1998) 90(21):1621–1625.
   PubMedGoogle Scholar
• ••A classic case report demonstrating efficacyof combining retinoic acid with phenylbutyrate for treatment of retinoid-resistant APL.
   Google Scholar
• PHIEL CJ, ZHANG F, HUANG EY, GUENTHER MG, LAZAR MA, KLEIN PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Biol. Chem. (2001) 276(39):36734–36741.
   Web of Science ®Google Scholar
• LO COCO F, NERVI C, AVVISATI G, MANDELLI F: Acute promyelocytic leukemia: a curable disease. Leukemia (1998) 12(12):1866–1880.
   PubMed Web of Science ®Google Scholar
• MATTHAY KK, VILLABLANCA JG, SEEGER RC et al.: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N EngL I Med. (1999) 341(16):1165–1173.
   PubMed Web of Science ®Google Scholar
• HENNEY JE: From the Food and Drug Administration. JAMA (2000) 283(9):1131.
   PubMedGoogle Scholar
• ESTEVA FJ, GLASPY J, BAIDAS S et al: Multicenter Phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol (2003) 21(6):999–1006.
   PubMed Web of Science ®Google Scholar
• VERONESI U, DE PALO G, MARUBINI E et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. Natl. Cancer Inst. (1999) 91(21):1847–1856.
   Google Scholar
• ••A randomised trial of fenretinide in breastcancer with a possible benefit in premenopausal women.
   Google Scholar
• TRONSTAD K, BERGE K, FLINDT E, KRISTIANSEN K, BERGE R: Optimization of methods and treatment conditions for studying effects of fatty acids on cell growth. Lipids (2001) 36:305–313.
   PubMed Web of Science ®Google Scholar
• GRAV HJ, TRONSTAD KJ, GUDBRANDSEN OA et al.: Changed energy state and increased mitochondrial 13-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression. Evidence for peroxisome proliferator-activated receptor-a independent induction of UCP-2 expression. I Biol. Chem. (2003) 278(38):30525–30533.
   Google Scholar
• SPECTOR AA, BURNS CP: Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res. (1987) 47(17):4529–4537.
   PubMed Web of Science ®Google Scholar
• PETERSEN ES, KELLEY EE, MODEST EJ, BURNS CP: Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res. (1992) 52(22):6263–6269.
   Google Scholar
• HARDMAN WE: Omega-3 fatty acids to augment cancer therapy. Num (2002) 132(11 Suppl.):S3508–S3512.
   Google Scholar
• LOCKWOOD K, MOESGAARD S, HANIOKA T, FOLKERS K: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Ma Aspects Med. (1994) 15(Suppl.):S231–S240.
   Google Scholar
• WIGMORE SJ, ROSS JA, FALCONER JS et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition (1996) 12(1 Suppl.):S27–S30.
   Google Scholar
• ANTI M, ARMELAO F, MARRA G et al: Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology (1994) 107(6):1709–1718.
   PubMed Web of Science ®Google Scholar
• MCILLMURRAY MB, TURKIE W: Controlled trial of 7 linolenic acid in Duke's C colorectal cancer. Br. Med. (Clin. Res. Ed.) (1987) 294(6582):1260.
   PubMedGoogle Scholar
• KA_PmALI RA: Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Nutrition (1996) 12(1 Suppl.):S2–S4.
   Google Scholar
• DAS UN, PRASAD VV, REDDY DR: Local application of y-linolenic acid in the treatment of human gliomas. Cancer Lett. (1995) 94(2):147–155.
   PubMed Web of Science ®Google Scholar
• BELURY MA: Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. Num (2002) 132(10):2995–2998.
   Google Scholar
• MILNER JA: A historical perspective on garlic and cancer. J. Num. (2001) 131(3s):S1027–S1031.
   Google Scholar
• PIZER ES, THUPARI J, HAN WF et al: Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. (2000) 60(2):213–218.
   PubMed Web of Science ®Google Scholar
• MAGNARD C, BACHELIER R, VINCENT A et al: BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene (2002) 21(44):6729–6739.
   PubMed Web of Science ®Google Scholar
• RUBIN MA, ZHOU M, DHANASEKARAN SM et al: a-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 287(13):1662–1670.
   PubMed Web of Science ®Google Scholar